Famciclovir Tablets (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg per dose orally 3 times daily for 7 days. It is recommended that treatment be started as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer 250 mg of this medicine per dose orally 3 times daily for 5 days. It is recommended that treatment be started as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer 125 mg of this medicine per dose orally 2 times daily for 5 days. It is recommended that treatment be started during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this medicine per dose orally 2 times daily. Discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Because creatinine clearance of this medicine is reduced in patients with renal impairment, dose adjustments should be made with caution. The dosage for these patients is as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose 2 times daily 10～29 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 125 mg per dose 2 times daily 10～29 125 mg per dose once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose 2 times daily 10～29 125 mg per dose 2 times daily 4) If only serum creatinine is known, creatinine clearance may be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, it is recommended that this medicine be administered every 48 hours, taking the dialysis interval into account. A 4-hour hemodialysis session reduces the plasma concentration of this medicine by approximately 75%, so administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary for patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This medication should not be used in patients who have had hypersensitivity to this drug or its components, particularly the active substance, penciclovir. Additionally, this drug contains lactose, so it should not be administered to patients with hereditary issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients with renal impairment should use this medication with caution, and dosage adjustments may be necessary. During treatment with this medication, symptoms such as headache, dizziness, nausea, vomiting, abdominal pain, and diarrhea may occur, and rarely, side effects like thrombocytopenia or palpitations have been reported. Skin rash or itching, and rarely serious skin reactions may also occur, so any unusual symptoms should be consulted with a healthcare provider immediately. This medication does not cure genital herpes, so it is important to avoid sexual contact and maintain safe sexual relations during treatment if any symptoms are present. If central nervous system symptoms such as dizziness or drowsiness occur, it is advisable to refrain from driving or operating machinery. Patients with mild to moderate liver dysfunction do not require special dosage adjustments, but caution is necessary as the effectiveness may decrease in patients with severe liver impairment. There is a low possibility of drug interactions, but caution is needed when used with certain drugs like probenecid as it may increase blood concentration. Pregnant or breastfeeding women should only use this drug when the treatment benefit outweighs the risk, as its safety has not been fully established. The use of this medication in children under 18 years is not recommended, as its safety and effectiveness have not been confirmed. Generally, elderly patients do not require dosage adjustments, but dosage should be adjusted if renal function is impaired. In cases of overdose, appropriate treatment should be followed, and blood dialysis may be utilized to lower drug concentration if necessary. This medication should be stored in a dry place below 30 degrees Celsius and kept in a safe location out of reach of children, and it should not be transferred to another container.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it should be kept in a dry place below 30 degrees Celsius to maintain its efficacy.

Appearance

White, round film-coated tablets

Package unit

Bottle - 30 tablets/bottle